除口服皮质类固醇外,抗生素治疗成人哮喘加重的实际有效性。

IF 3.4 3区 医学 Q1 RESPIRATORY SYSTEM
Irene Mommers, Sumaira Mubarik, Job F M van Boven, Jens H Bos, Maarten J Bijlsma, Eelko Hak
{"title":"除口服皮质类固醇外,抗生素治疗成人哮喘加重的实际有效性。","authors":"Irene Mommers, Sumaira Mubarik, Job F M van Boven, Jens H Bos, Maarten J Bijlsma, Eelko Hak","doi":"10.1136/bmjresp-2025-003506","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antibiotics are widely used to manage acute asthma exacerbations, despite little evidence for their effectiveness. This study assesses the added value of antibiotics alongside oral corticosteroids (OCSs) in treating asthma exacerbations.</p><p><strong>Methods: </strong>This retrospective cohort study included individuals from the Netherlands between 1994 and 2022 from the IADB.nl pharmacy dispensing database. Individuals had to be 16-45 years old, use inhaled asthma medication and have a first recorded prednisone/prednisolone (OCS) dispense of ≥30 mg/day for 3-14 days. Patients were compared regarding treatment failure (a new dispense of OCS or antibiotics, 15-30 days after initial dispense), based on whether or not they were dispensed antibiotics (AB) alongside their first recorded OCS dispense. Regression analyses with inverse probability of treatment weighting were used to adjust for various confounders.</p><p><strong>Results: </strong>Of the 5401 individuals included, 38% received antibiotics alongside the first-recorded OCS dispense, with a decreasing trend from 47% in 2009 to 24% in 2020. The OR for treatment failure was 1.36 (95% CI 0.81 to 2.16) for AB+OCS versus OCS-only. The HR for a new exacerbation within 31-365 days of follow-up was 1.20 (95% CI 0.92 to 1.56) for AB+OCS versus OCS-only. The lack of beneficial effect of AB was consistent across subcohorts.</p><p><strong>Conclusions: </strong>This study found no reduction in treatment failure, nor in risk of subsequent exacerbation, from adding AB to OCS for treating acute asthma exacerbations. We suggest that antibiotics should not be used in primary care settings to treat acute asthma exacerbation unless there are clear signs of bacterial infection.</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"12 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world effectiveness of antibiotics in addition to oral corticosteroids for managing asthma exacerbations in adults.\",\"authors\":\"Irene Mommers, Sumaira Mubarik, Job F M van Boven, Jens H Bos, Maarten J Bijlsma, Eelko Hak\",\"doi\":\"10.1136/bmjresp-2025-003506\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antibiotics are widely used to manage acute asthma exacerbations, despite little evidence for their effectiveness. This study assesses the added value of antibiotics alongside oral corticosteroids (OCSs) in treating asthma exacerbations.</p><p><strong>Methods: </strong>This retrospective cohort study included individuals from the Netherlands between 1994 and 2022 from the IADB.nl pharmacy dispensing database. Individuals had to be 16-45 years old, use inhaled asthma medication and have a first recorded prednisone/prednisolone (OCS) dispense of ≥30 mg/day for 3-14 days. Patients were compared regarding treatment failure (a new dispense of OCS or antibiotics, 15-30 days after initial dispense), based on whether or not they were dispensed antibiotics (AB) alongside their first recorded OCS dispense. Regression analyses with inverse probability of treatment weighting were used to adjust for various confounders.</p><p><strong>Results: </strong>Of the 5401 individuals included, 38% received antibiotics alongside the first-recorded OCS dispense, with a decreasing trend from 47% in 2009 to 24% in 2020. The OR for treatment failure was 1.36 (95% CI 0.81 to 2.16) for AB+OCS versus OCS-only. The HR for a new exacerbation within 31-365 days of follow-up was 1.20 (95% CI 0.92 to 1.56) for AB+OCS versus OCS-only. The lack of beneficial effect of AB was consistent across subcohorts.</p><p><strong>Conclusions: </strong>This study found no reduction in treatment failure, nor in risk of subsequent exacerbation, from adding AB to OCS for treating acute asthma exacerbations. We suggest that antibiotics should not be used in primary care settings to treat acute asthma exacerbation unless there are clear signs of bacterial infection.</p>\",\"PeriodicalId\":9048,\"journal\":{\"name\":\"BMJ Open Respiratory Research\",\"volume\":\"12 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open Respiratory Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjresp-2025-003506\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2025-003506","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:抗生素被广泛用于治疗急性哮喘发作,尽管很少有证据表明其有效性。本研究评估了抗生素与口服皮质类固醇(OCSs)治疗哮喘加重的附加价值。方法:这项回顾性队列研究包括1994年至2022年间来自荷兰IADB的个体。Nl药房调剂数据库。受试者年龄必须在16-45岁之间,使用吸入性哮喘药物,并且首次记录强的松/强的松(OCS)配药≥30mg /天,持续3-14天。根据患者是否在首次记录的OCS配药的同时配药抗生素(AB),比较患者的治疗失败情况(首次配药后15-30天的OCS或抗生素新配药)。采用处理加权逆概率回归分析来调整各种混杂因素。结果:在纳入的5401名患者中,38%的患者在首次记录的OCS处方中同时使用抗生素,从2009年的47%下降到2020年的24%。AB+OCS治疗失败的OR为1.36 (95% CI 0.81 - 2.16)。在31-365天的随访中,AB+OCS与仅OCS的新加重的HR为1.20 (95% CI 0.92至1.56)。AB缺乏有益效果在各个亚群中是一致的。结论:本研究发现,在OCS中加入AB治疗急性哮喘加重,既没有降低治疗失败,也没有降低随后加重的风险。我们建议,除非有明显的细菌感染迹象,否则初级保健机构不应使用抗生素治疗急性哮喘加重。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Real-world effectiveness of antibiotics in addition to oral corticosteroids for managing asthma exacerbations in adults.

Background: Antibiotics are widely used to manage acute asthma exacerbations, despite little evidence for their effectiveness. This study assesses the added value of antibiotics alongside oral corticosteroids (OCSs) in treating asthma exacerbations.

Methods: This retrospective cohort study included individuals from the Netherlands between 1994 and 2022 from the IADB.nl pharmacy dispensing database. Individuals had to be 16-45 years old, use inhaled asthma medication and have a first recorded prednisone/prednisolone (OCS) dispense of ≥30 mg/day for 3-14 days. Patients were compared regarding treatment failure (a new dispense of OCS or antibiotics, 15-30 days after initial dispense), based on whether or not they were dispensed antibiotics (AB) alongside their first recorded OCS dispense. Regression analyses with inverse probability of treatment weighting were used to adjust for various confounders.

Results: Of the 5401 individuals included, 38% received antibiotics alongside the first-recorded OCS dispense, with a decreasing trend from 47% in 2009 to 24% in 2020. The OR for treatment failure was 1.36 (95% CI 0.81 to 2.16) for AB+OCS versus OCS-only. The HR for a new exacerbation within 31-365 days of follow-up was 1.20 (95% CI 0.92 to 1.56) for AB+OCS versus OCS-only. The lack of beneficial effect of AB was consistent across subcohorts.

Conclusions: This study found no reduction in treatment failure, nor in risk of subsequent exacerbation, from adding AB to OCS for treating acute asthma exacerbations. We suggest that antibiotics should not be used in primary care settings to treat acute asthma exacerbation unless there are clear signs of bacterial infection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Open Respiratory Research
BMJ Open Respiratory Research RESPIRATORY SYSTEM-
CiteScore
6.60
自引率
2.40%
发文量
95
审稿时长
12 weeks
期刊介绍: BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信